ImmunityBio (IBRX) Other Non Operating Income (2015 - 2026)
ImmunityBio (IBRX) posted quarterly Other Non Operating Income of $1.1 million for Q1 2026, down 80.14% year-over-year from $5.6 million in Q1 2025, and down 83.95% quarter-over-quarter from $6.9 million in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Other Non Operating Income (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Other Non Operating Income for 12 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 80.14% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $10.2 million (up 170.44% YoY), while the FY2025 annual figure was $6.4 million, up 42753.33% from the prior year.
- Other Non Operating Income slipped to $1.1 million in Q1 2026 per IBRX's latest filing, from $6.9 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $6.9 million in Q4 2025 and bottomed at -$20.1 million in Q4 2024.
- Historically, Other Non Operating Income has averaged -$507600.0 across 5 years, with a median of $6000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non Operating Income tumbled 26825.0% — and 2025, when it surged 27990.0%.
- ImmunityBio's Other Non Operating Income stood at -$187000.0 in 2022, then plunged by 1088.77% to -$2.2 million in 2023, then slumped by 804.14% to -$20.1 million in 2024, then jumped by 134.35% to $6.9 million in 2025, then tumbled by 83.95% to $1.1 million in 2026.
- Business Quant data shows IBRX's Other Non Operating Income at $1.1 million in Q1 2026, $6.9 million in Q4 2025, and $289000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.52 Bn | 8.16 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -692,000.00 |
| Mar 31, 2026 | -5.92 Mn |
| Dec 31, 2025 | -1.40 Mn |
| Sep 30, 2025 | 289,000.00 |
| Jun 30, 2025 | 1.93 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | -6.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 21.19 Mn |
| Mar 31, 2024 | -2.72 Mn |
| Dec 31, 2023 | -71,000.00 |
| Sep 30, 2023 | -1.05 Mn |
| Jun 30, 2023 | -28,000.00 |
| Mar 31, 2023 | -1.08 Mn |
| Dec 31, 2022 | -923,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 185,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | -59,000.00 |
| Sep 30, 2021 | -38,000.00 |